Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.34 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766726 | 0.74 | ALDH1A1 (0.53) | ALDH1A1MAPTTDP1HIF1AEPAS1 | |
| SCHEMBL229716 | 0.74 | EZH2 (0.59) | ALDH1A1MAPTKDM4EEZH2HPGD | |
| SCHEMBL14873891 | 0.70 | RIPK1 (0.55) | — | |
| SCHEMBL24493715 | 0.70 | PDGFRB (0.36) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL18946289 | 0.69 | ERN1 (0.33) | ALDH1A1TSHRTDP1KDM4EPRKDC | |
| SCHEMBL231362 | 0.68 | PRKDC (0.46) | ALDH1A1MAPTTSHRTDP1KDM4E | |
| SCHEMBL13568565 | 0.68 | MAP2K1 (0.53) | ALDH1A1MAPTTDP1KDM4EHPGD | |
| SCHEMBL229717 | 0.67 | PDGFRB (0.46) | MAPT | |
| SCHEMBL18945838 | 0.66 | BRD4 (0.33) | ALDH1A1TSHRTDP1KDM4EERN1 | |
| SCHEMBL10154742 | 0.66 | TUBB1 (0.49) | ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016176450-A1 | TAMBJAMINES AND B-RING FUNCTIONALIZED PRODIGININES | PORTLAND STATE UNIVERSITY (US) | 2016-11-03 | — | — | WO | disclosed |
| US-7491745-B2 | Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| EP-1431286-A2 | Prodigiosin derivatives for treating cancer or viral diseases | Gemin X Biotechnologies Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| EP-1255753-B1 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | GEMIN X BIOTECHNOLOGIES INC (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2004-01-22 | — | — | US | disclosed |
| US-6602879-B2 | For inhibiting the replication or infectivity of a virus; therapy | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-08-05 | — | — | US | disclosed |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | ALDH1A1 3326/4885MAPT 2438/4885TSHR 4715/4885 |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | ALDH1A1 3326/4885MAPT 2438/4885TSHR 4715/4885 |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | POLI, PCNA, ELL | ALDH1A1 2915/4885MAPT 4492/4885TSHR 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.